| titleOfInvention |
antibody or antigen-binding fragment thereof, antibody or antigen-binding fragment that specifically bind to a human cd25 epotype, affinity-matured variant, nucleic acid molecule and vector, host cell, method for producing an antibody or antigen binding fragment thereof, composition, pharmaceutical composition, use of an antibody or antigen binding fragment thereof, method for treating cancer in an individual, method for depleting regulatory t cells in a tumor in an individual, antibody or fragment antigen-binding compound that competes with an antibody, kit, method for preparing an anti-cd25 antibody and method for preparing a pharmaceutical composition |
| abstract |
antibody or antigen-binding fragment thereof, antibody or antigen-binding fragment that specifically bind to a human cd25 epotype, affinity-matured variant, nucleic acid molecule and vector, host cell, method for producing an antibody or antigen binding fragment thereof, composition, pharmaceutical composition, use of an antibody or antigen binding fragment thereof, method for treating cancer in an individual, method for depleting regulatory t cells in a tumor in an individual, antibody or fragment antigen-binding competitor with an antibody, kit, method for preparing an anti-cd25 antibody and method for preparing a pharmaceutical composition. the present disclosure provides antibody sequences found in antibodies that bind to human cd25. in particular, the present disclosure provides sequences of anti-human cd25 antibodies, which do not block the binding of cd25 to il-2 or il-2 signaling. antibodies and antigen-binding portions thereof that include such sequences can be used in pharmaceutical composition and treatment methods, in particular to treat cancer. |